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Abstract 
Communication between insulin target tissues and beta-cells initiate compensatory responses which 
increase insulin production. Correlated changes, in gene expression between tissues, can provide 
evidence for such intercellular communication. We profiled gene expression studies in Type 2 
diabetic subjects to unveil the mechanistic factors involved. Our results showed that genes involved 
in carbohydrate, lipid and amino acid metabolism pathways, glycan of biosynthesis, metabolism 
of cofactors and vitamin pathways, ubiquitin-mediated proteolysis, signal transduction pathways, 
neuroactive ligand receptor interaction were upregulated in diabetes compared to healthy subjects. 
In contrast, genes involved in cell adhesion, cytokine-cytokine receptor interaction, insulin signaling, 
PPAR signaling pathways were downregulated in subjects with type 2 diabetes mellitus (T2DM). 
~2-microglobulin, a MHC class I molecule was strongly downregulated in diabetic subjects. Further, 
genes involved in inflammatory pathway are differentially expressed in subjects with T2DM. Hence, 
it was evident that genes concerned with pathways of carbohydrate, lipid and amino acid metabolism, 
neuronal function and inflammation playa significant role in the pathobiology ofT2DM. 
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Introduction are characteristics ofthis disease. The abnonnalities include 
central obesity, hypertension, accelerated atherosclerosis, 
Type 2 diabetes mellitus (T2DM) is a disorder that involves hypertriglyceridemia and low serum concentrations ofhigh 
an increased demand for insulin brought about by insulin density lipoproteins [2,3]. 
resistance, together with a failure to compensate with 
sufficient insulin production. Although insulin resistance One way to understand the pathophysiology of diabetes is 
occurs in most obese individuals, diahetes is generally to examine the coordinated changes in gene expression in 
forestalled through compensation with increased insulin. T2DM. In each case, there are groups ofgenes that undergo 
This increase in insulin occurs through an expansion ofbeta­ changes in expression in a highly correlated fashion. 
cell mass and/or increased insulin secretion by individual Genomic approaches to detennine differential expression 
beta-cells. Failure to compensate for insulin resistance profiles utilizing serial analysis of gene expression 
leads to T2DM. (SAGE) [4] and DNA microarrays [5] are now providing 
global views of the potential genes and pathways that are 
T2DM is one of the most challenging health problems in associated with diabetes. Utilizing these approaches, tissue­
many developing and industrialized countries [I]. The exact specific gene expressions in human pancreas, muscle and 
cause of T2DM, which affects millions of people all over fat demonstrated differential regulation of approximately 
the world, is not known. One of the foremost challenges 800 genes in diabetes [5]. 
we face is to account mechanistically for not only the 
definition of hyperglycemia, but also for the myriad of Systemically circulating peripheral blood mononuclear 
other biochemical and physiological abnonnalities, which cells (PBMCs) are considered unique tissue affected by 
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the host condition and may reflect oxidative stress caused 
by high levels of glucose, insulin, free fatty acids, and 
tissue-derived circulating bioactive mediators. To verify 
the hypothesis that the gene expression ofPBMCs changes 
in response to diabetic circumstances, we comprehensively 
compared global gene expression profiles of PBMCs 
between patients with and without T2DM by using 
Reverse Transcription Quantitative Real Time PCR array 
technology. Even though there is extensive literature 
relating peripheral blood cells to diabetic complications, 
the association of gene expression changes in PBMCs in 
T2DM is largely unknown. In this study, we examined 
gene expression profiles ofperipheral blood cells in T2DM 
to identify potential gene signatures. 
Material and Methods 
Study subjects 
The study population was composed of six type 2 diabetics 
and three normal subjects from the mixed races ofMalaysian 
population. Patients were in the age group 30-05 years . .The 
clinical characteristics of the study subjects wcrc rccorded. 
Anthropometric measurements 
Anthropomctric measurements, like weight and height, 
were obtained using standardized techniques as detailed 
elsewhere [0]. Height was measured with a tape to the 
nearest cm. Weight was measured with traditional spring 
balance that was kept on a firm horizontal surface. The 
body mass index (BMI) was calculated using the formula 
BM I =	 Weight (kg) 
Height (m') 
Laboratory studies 
After an overnight fast, venous blood samples wcrc 
withdrawn from each paticnt in sterile EDTA tubes. Serum 
samples were assayed for plasma glucose, HbA 1C, total 
cholesterol, triglycerides and HDL cholesterol. 
Processing ofblood samples 
Blood was collected in EDTA tubes. PBMCs were isolated 
using Ficoll gradients within 4h of each blood draw; ifnot 
processed immediately, cells were lysed in RLT buffer 
containing ~-mercaptoethanoland stored at minus 80 C. 
Isolation ofRNA from PBMCs 
Mononuclear cells were isolated by the Ficoll density­
gradient method as previously described [7]. Total RNA 
was extracted using an RNA isolation kit as per the 
manufacturer's protocol (SuperArray, catalog number PA­
00 I). RNA integrity was assessed using an Agilent 2100 
bio-anaIyzer (Agilent, Palo Alto, Ca). 
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PCR arrays 
From 0.5-1.0 !J.g of total RNA, double-stranded cDNA 
was generated using a cDNA synthesis kit (SA Bioscience, 
Catalog. Number C-03) that eliminated genomic DNA 
contamination. cDNA was used as a template for SYBR­
green based RT2-qPCR array using the diabetes array plate 
(SA Biosciences). 
Statistical analysis 
All data is expressed as means plus/minus SO. Statistical 
analysis of the results was perfom1ed by student't' test. 
Values were considered significant when p was less than 
0.0001. 
Results and Discussion 
In this study, we demonstrate the possibility that gene 
expression profile in PBMCs reflects the pathophysiology 
of T2DM. As T2DM is a multifactorial disorder [8], a 
comprehensive approach identifying biological pathways 
or co-regulated gene sets associated with the diseases 
is required to understand the molccular signature of 
T2DM [9]. Thus, we screened known human pathways and 
extracted information on the metabolic pathways that were 
significantly altered in the PBMCs of the diabetic subjects. 
Clinical characteristics of control subjects and patients with 
diabetcs arc shown in Table 1. Age, BMI, and levels offasting 
plasma glucose, HbA I c, total cholesterol. triglyceride and 
LDL-cholesterol were significantly increased while HDL­
cholesterol was found to be decreased in paticnts with 
T2DM. 
Table J: Clinical characteristic.'- ofpatients with T2DM 
(n = 6) and normal subjects (n=3) 
Healthy controls nOM 
M:F 1:2 3:3 
Age, Yr 34.7 9.07 53.5 7.4' 
8M I. Kg/m2 22.07 1.78 26.7 1.93' 
Fasting plasma glucose 4.5 0.45 11.5 1.36" 
(mmol/L) 
HbAlc (%) 5.49 0.13 11.1 0.68" 
Total cholesterol 4.73 0.25 7.03 0.34" 
(mmoIiL) 
Triglyceride 1.70 0.26 4.!B 0.44" 
(mmol/L) 
HDL cholesterol 2.14 0.17 1.04 0.04" 
(mmol/L) 
LDL cholesterol 2.25 0.15 4.87 0.18" 
(mmol/L) 
Dala are expressed as Mean ± SD. *P < 0.01, **p < 0.0001 as 
compared 10 control. 
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Gene expression profiling is a powerful alternative strategy 1. Receptors, transporters and channels 
to test for differences in expression of pre-defined clusters 2. Nuclear receptors 
or networks of genes rather than individual genes, thus 3. Metabolic enzymes 
reducing the number of tested hypotheses. Gene expression 4. Secreted factors 
analysis using RNA extracted from peripheral blood cells 5. Signal Transduction molecules 
ofsubjects with T2DM showed significant alterations in the 6. Transcription factors. 
expression of84 candidate genes (Table 2). For the purpose 
of analysis, genes were clustered functionally into It is possible to predict and understand pathological 
Table 2: Fold change in gene expression in subjects with T2DM over normal subjects 
Unigene Genbank Position Symbol Description Fold change 
T20 vs C 
I-Is.54470 NM 000352 AO\ ABCC8 ATP-binding cassette, sub-family C (CFTRJMRP), member 8 -1.35 
I-Is298469 NM 152831 A02 ACE Angiotensin I converting enzyme (peptidyl-dipeptidase A) I 2.10 
I-Is.387567 NM 001096 A03 AClY ATP citratc lyase 1.45 
I-Is.2549 NM 000025 A04 AORB3 Adrenergic, beta-3-, rcceptor -1.20 
I-Is.19383 NM 000029 A05 AGT Angiotensinogen (serpin peptidase inhibitor, clade A. mcmber 1.48 
8) 
I-Is.63 1535 NM 001626 A06 AKT2 V-akt murine thymoma viral oncogene homolog 2 -1.35 
I-Is.130730 NM 000486 A07 AQP2 Aquaporin 2 (collecting duct) -1.36 
I-Is.514821 NM 002985 A08 CCl5 Chemokine (C-C motif) ligand 5 1.48 
I-Is.644637 NM 000648 A09 CCR2 Chemokine (C-C motif) receptor 2 1.66 
I-Is.591629 NM 006139 A10 C028 C028 molecule -1.70 
I-Is.512682 NM 001712 All CEACAMI Carcinoembryonic antigen-related cell adhesion molccule 1 -1.37 
(biliary glycoprotein) 
I-Is.76171 NM 004364 AI2 CEBPA CCAAT/cnhancer binding protcin (C/EBP). alpha 1.86 
I-Is.247824 NM 005214 BOl CTLA4 Cytotoxic T-lymphocytc-associated protein 4 -1.28 
I-Is.417962 NM 057158 B02 DUSP4 Dual specificity phosphatase 4 1.68 
I-Is.527295 NM 006208 B03 ENPPI Ectonuc lCOtlde pyrophosphatase/phosphodiesterase I 2.11 
I-Is.494496 NM 000507 B04 FBPl Fructose-I,6-bisphosphatase 1 1.33 
I-Is.436448 NM 005251 B05 FOXC2 Forkhead box C2 (MFI-I-I, mesenchyme forkhcad 1) -1.50 
I-Is.632336 NM 005249 B06 FOXGIB Forkhcad box G IB -1.19 
I-Is.247700 NM 014009 B07 FOXP3 Forkhead box P3 -1.51 
I-Is.212293 NM 000151 B08 G6PC Glucose-6-phosphatase, catalytic subunit 2.11 
I-Is.461047 NM 000402 B09 G6PD Glueose-6-phosphate dehydrogenase -1.34 
I-Is.5 16494 NM 002054 B10 GCG Glucagon 1.66 
I-Is.208 NM 000160 BII GCGR Glucagon receptor 1.36 
I-Is.I270 NM 000162 Bl2 GCK Glucokinase (hexokinase 4, maturity onset diabetes of the -1.6\ 
young 2) 
I-Is.389103 NM 002062 COl GlPIR Glucagon-like peptide I receptor -1.34 
I-Is.524418 NM 005276 CO2 GPDl Glycerol-3-phosphate dchydrogcnase 1 (soluble) -1.19 
I-Is.445733 NM 002093 C03 GSK3B Glycogen synthase kinase 3 beta 1.80 
I-Is.517581 NM 002133 C04 I-IMOXI I-Ieme oxygenase (decyc1ing) 1 1.49 
I-Is.116462 NM 178849 C05 I-INF4A I-Iepatocyte nuelear factor 4, alpha -1.54 
I-Is.643447 NM 000201 C06 ICAMl Intercellular adhesion molecule 1 (C054), human rhinovirus 
-
1.49 
receptor 
I-Is.500546 NM 004969 C07 IDE Insulin-degrading enzyme -1.07 
I-Is.856 NM 000619 C08 IFNG Interferon, gamma 1.67 
I-Is.635441 NM 000599 C09 IGFBP5 Insulin-like growth factor binding protein 5 -1.42 
I-Is.413513 NM 001556 CIO IKBKB Inhibitor ofkappa light polypeptide gene enhancer in B-cells, -1.20 
kinase beta 
I-Is.193717 NM 000572 C11 ILIO Interleukin 10 -1.53 
I-Is.674 NM 002187 C12 ILl2B Interleukin 12B (natural killer cell stimulatory factor 2, 1.69 
cytotoxic lymphocyte maturation 
Biomedical Research, Volume 20, Issue 3 160 
Leucocytes gene profiles in diabetic subjects 
Hs.513457 NM 000418 DOl IL4R Interl eukin 4 receptor 1.17 
Hs.512234 NM 000600 D02 IL6 Interleukin 6 (interferon, beta 2) 1.17 
Hs.523875 NM 001567 D03 I1\PPLI Inositol polyphosphate phosphatase-like I IA8 
Hs.89832 NM 000207 D04 INS Insulin -1.56 
HsA65744 NM 000208 D05 INSR Insulin receptor -1.69 
Hs.32938 NM 000209 D06 PDXI Pancreatic and duodenal homeobox I -1.68 
HsA71508 NM 005544 D07 IRSI Insulin receptor substrate I -1.53 
HsA42344 NM 003749 D08 IRS2 Insulin receptor substrate 2 -1.34 
Hs.588289 NM 001315 D09 MAPKI4 Mitogen-activated protein kinase 14 1.20 
HS.138211 NM 002750 DIO MAPK8 Mitogen-activated protein kinase 8 1.66 
Hs.21160 NM 002395 DII MEl Malic enzyme I, NADP(+)-dependent, cytosolic -1.82 
HS.72981 NM 002500 DI2 NEURODI Neurogenic differentiation I -1.60 
HsA31926 NM 003998 EOI NFKBI Nuc lear factor of kappa light polypeptide gene enhancer in IA8 
B-cells I (pI05) 
HS.653170 NM 000603 E02 NOS3 Nitric oxide synthase 3 (endothelial cell) -1.51 
Hs.298069 NM 005011 E03 NRFI Nuclear respiratory factor I -1.35 
HsA31279 NM 006178 E04 NSF N-ethylmaleimide-sensitive factor -1.34 
HS.I77766 NM 001618 E05 PARP] Poly (ADP-ribose) polymerasc family, mcmber I 1.79 
HsA97487 NM 002646 E06 PIK3C2B Phosphoinositide-3-kinasc, class 2, beta polypeptide -1.20 
HS.518451 NM 005026 E07 PIK3CD Phosphoinositide-3-kinase, catalytic, delta polypeptide -1.19 
Hs.132225 NM 
-
18]504 E08 PIK3R I Phosphoinositide-3-kinase, regulatory subunit I (p85 alpha) -1.36 
Hs.I03110 NM 005036 E09 PPARA Peroxisome proliferative activated receptor, alpha 1.67 
Hs.162646 NM 015869 EIO PPARG Pcroxisome proliferator-activatcd receptor gamma -1.20 
HS.527078 NM 013261 Ell PPARGCIA Peroxisome proliferator-activated receptor gamma, coactivator -1.27 
I alpha 
Hs.591261 NM 
-
133263 EI2 PPARGCIB Peroxisomc proliferator-actlvated receptor gamma, coactivator -1.06 
I beta 
HsA3322 NM 006251 FOI PRKAAI Protein kinase, AMP-activated, alpha I catalytic subunit -1.27 
Hs.549162 NM 016203 F02 PRKAG2 Protein kinase, AMP-activated, gamma 2 non-catalytic subunit -1.20 
HsA60355 NM 002738 F03 PRKCBI Protein kinase C, beta I IA7 
HsAI7549 NM 002827 F04 PTPNI Protein tyrosine phosphatase, non-receptor type I 1.78 
Hs.282417 NM 002863 F05 PYGL Phosphorylase, glycogen; liver (Hers disease, glycogen 1.27 
storage disease type VI) 
Hs.296169 NM 004578 F06 RAB4A RAB4A, member RAS oncogene family -1.51 
Hs.283091 NM 020415 F07 RETN Resistin 1.87 
Hs.82848 NM 000655 F08 SELL Selectin L (lymphocyte adhesion moleculc I) -1.20 
Hs.380691 NM 001042 F09 SLC2A4 Solute carrier family 2 (facilitated glucose transporter), -1.21 
member 4 
Hs.511149 NM 003825 FlO SNAP23 Synaptosomal-associated protein, 23kDa -1.35 
HS.167317 NM 003081 FIl SNAP25 Synaptosomal-associated protein, 25kDa -1.51 
Hs.592123 NM 004176 FI2 SREBFI Sterol regulatory element binding transcription factor I -IA4 
HS.83734 NM 004604 GOI STX4 Syntax in 4 -1.07 
Hs.288229 NM 003165 G02 STXBPI Syntaxin binding protein I -1.34 
HS.534352 NM 006949 G03 STXBP2 Syntaxin binding protein 2 -1.51 
Hs.191144 NM 006481 G04 TCF2 Transcription factor 2, hepatic; LF -B3; variant hepatic nuclear -1.21 
factor 
Hs.645227 NM 000660 G05 TGFBI Transforming growth factor, beta I IA8 
Hs.94367 NM 003317 G06 TITFI Thyroid transcription factor I -1.52 
Hs.241570 NM 000594 G07 TNF Tumor necrosis factor (TNF superfamily, member 2) 1.32 
Hs.279594 NM 001065 G08 TNFRSFIA Tumor necrosis factor receptor superfamily, member IA 1.66 
Hs.516826 NM 021158 G09 TRIB3 Tribbles homolog 3 (Drosophila) 1.67 
Hs.66708 NM 004781 GIO VAMP3 Vesicle-associated membrane protein 3 (cellubrevin) -1.32 
Hs.653207 NM 
-
194434 GIl VAPA (vesicle-associated membrane protein)-associated protein A, -1.35 
33kDa 
Hs.73793 NM 003376 GI2 VEGFA Vascular endothelial growth factor A 1.39 
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conditions by studying gene expression III blood 
cells [10,11]. Hence, we used such an approach to delineate 
similarities and differences in gene expression between 
nonnal and type 2 diabetic patients. 
Hierarchical clustering and heat map of the genes 
significantly regulated in diabetes showed distinct gene 
clusters that are unique to T2DM (Figure 1a and b). This 
demonstrates that gene expression signatures in PBMCs 
could potentially provide a mechanism to distinguish 
diabetic state from the normal state or to explain the 
pathophysiology ofdiabetes. Sixty per cent of significantly 
altered genes in the diabetic group were down regulated 
while 40% were up regulated when compared with the 
non-diabetic groups (Figure 2a and b). This relationship 
emphasizes how strikingly different the pattern of 
expression is between these two groups. 
We found that distinct pathophysiology ofpatients with type 
2 diabetes was reflected in coordinate alterations in the gene 
expression levels ofpathways involving carbohydrate, lipid 
and amino acid metabolism, insulin biosynthesis, secretion 
and its signaling mechanisms in the liver, pancreas, skeletal 
muscle and adipocytes and its co-factors. 
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Metabolic homeostasis has long been considered a major 
component in the pathophysiology ofdiabetes. In PBMCs, 
the genes encoding enzymes regulating carbohydrate and 
fat metabolism showed significant differential expression 
in diabetes. 
This shows that insulin regulation ofenergy homeostasis in 
PBMCs is distinctly different from other target tissue such 
as skeletal muscle and pancreas [12]. 
Genes encoding metabolic enzymes, receptors, substrates 
and signaling molecules (ENPPl, IDE, NEURODl, INSR, 
ABCC8, IRS 1, IRS2, INS, PXD-l, SNARE protein complex) 
that showed significant differential expression (Table 2) are 
known to playa role in insulin signaling and homeostasis. 
Protein kinases such as mitogen activated protein kinases 
(MAPK) were found to be up regulated and AMP-activated 
protein kinases (AMPK) were down regulated in T2DM but 
their association with the pathogenesis ofdiabetes is unclear. 
The liver is regarded as one of the central metabolic organs 
in the body, regulating and maintaining homeostasis. It 
performs most of the reactions involved in the synthesis 
and utilization of glucose. Diabetes results in a decrease 
in glucose utilization, an increase in glucose production, 
b 
Figure 1: Hierarchical cluster (a) andHeat map (b) illustration ofgene-expressionprofiles ofperipheral-bloodmononuclear 
cell (PEMe) samples from type 2 diabetics (n=6) and healthy controls (n=3). "Heat map, "which is the part ofthejigure 
containing colors (red, green, and black). The color represents the expression level of the gene. Red represents high 
expression, while green represents low expression. AO] to G]2 refer to positions shown in Table 2 
Biomedical Research, Volume 20, Issue 3 162 
Leucocytes gene profiles in diabetic subjects 
Group 1 "·S. Control Group 
,0.98 . 
0,48 
~-O.52
-§' 
e 
8.102
 
o
 t 
00 
o .
-' ,
·152 
• t I 
..
·2.02 
. r 
I' 
·]02 2.52 ~2.02 -152 -1.02 -O.5~ -0.02 flAX () 9:-1 
LORIO (Control Group 2" - DeUael) 
Figure 2 (a): Scatter plot analysis ol gene expression 
profiling on T2DM patients demonstrates differential gene 
expression. The y-axis represents log scores from T2DM 
patients (group I) and the x-axis represents log scoresfrom 
normal controls. Each symbol represents one gene within 
two-fold cutofrthreshold 
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Figure 2 (b): Volcano plot of log intensities for Control 
vs. T2DM Each circle corresponds to one gene represents 
the average log-ratio (log fold-change) in a two group 
comparison. The two-fold change method selects as 
differentially expressed all genes above the line 0.02 (up 
regulation) andbelow the line minus 0.02 (down regulation) 
increased angiogenesis, a reduced stress-defence system, 
and altered mitochondrial oxidative phosphorylation 
(OXPHOS) in insulin-dependent tissues such as 
liver [13,9,14]. A marked increase in the hepatic lipid 
concentration has been observed during diabetes [15-17]. 
In contrast, the rate of hepatic lipogenesis and related 
enzymes is decreased. Decreased glycolysis, impeded 
glycogenesis and increased gluconeogenesis are some of 
the changes ofglucose metabolism in the diabetic liver [18]. 
Patti et al. [19] in their study showed decreased expression 
of PGC I a coupled with reduced expression of NRF I 
and PPARy eventually result in decreased oxidative 
phosphorylation and lipid oxidation, accumulation oflipid 
in skeletal muscle and ultimately diabetes. In our studies on 
PBMCs, NRF I and PPARy were down regulated 1.35- and 
1.20-fold, respectively. 
Immunoregulation plays a significant role in diabetes and 
its pathogenesis. Enhanced expression and activation of 
transcription factor, nuclear factor KB and degradation 
of IKB triggers activation of genes involved in immune 
responses such as the pro-inflammaory cytokines (lL-4, 
TNF-a, IFN-y). IL-4, TNF-a and IFN-y expression was up 
regulated in our experiments, an indication ofactivation of 
the pathways of inflammation. An imbalance between Th I 
and Th2 cells has been shown to results in decreased activity 
of CD28 and CTLA4-mediated immunosuppressant and 
activation ofmacrophage-mediated inflammation involved 
in the process of ~-ccll destruction [20]. In PBMC both 
CD28 and CTL4 are downregulated and may be indicative 
of similar processes. 
In human eosinophils, intracellular signaling molecules 
ERK, p38 MAPK and c-Jun N-terminal protein kinase 
(JNK), together with proinflammatory cytokines IL-6, 
IL-I0, chemokines MCP-l/C-C chemokine receptor-2 
(CCR2), CXCL9/monokinc induced by interferon-y 
(MIG), CCL5/regulated upon activation normal T cell 
expressed and secreted (RANTES) and CXCLl O/IFN-y 
inducible protein-l 0 (lP-1 0) form a network in orchestrating 
inflammation in diabetes [21,22]. Our results show 
upregulation ofCCL2, CCL5, IL-6 and MAPKs 8 and 14 in 
diabetes indicating triggering ofproinflammatory pathways. 
Regulation of cell adhesion molecules plays an important 
role in vascular complications in T2DM. Intracellular 
adhesion molecule-I (lCAM I) is a member of the 
immunoglobulin super-family ofadhesion molecules. This 
type I membrane protein mediates leukocyte-endothelial 
cell adhesion and signal transduction, may playa role 
in the development of atherosclerosis. In the retina, its 
increased expression contributes to the microcirculation 
dysfunction by increasing leucocyte adhesion, aggregation 
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and migration in retinal vasculature [23]. In PBMC, ICAM I 
expression is markedly elevated and this would enhance 
leucocyte adhesion. Plasma concentrations of ICAM I, in 
patients with T2DM are more reflective of hyperglycemia 
than hyperinsulinemia or insulin resistance [24]. 
In summary, the current study demonstrates that 84 gene 
transcripts, involved in a variety offunctions, were altered in 
PBMCs ofpeople with T2DM. Results ofthis study suggest 
that there are significant differences in the expression 
of various genes concerned with carbohydrate, lipid, 
and protein metabolism, ubiquitin-mediated proteolysis, 
signal transduction pathways, neuroactive ligand-receptor 
interaction, cell adhesion molecules, cytokine-cytokine 
receptor interaction, insulin signaling and immune system 
pathways, oxidative phosphorylation, and PPAR signaling 
pathways in subjects with T2DM compared to normal. 
These alterations in gene transcripts may represent the 
response to increased circulating insulin levels necessary 
to maintain normal glucose levels in these patients. Further, 
studies on important known and novel targets regulated in 
T2DM in peripheral blood cells identified in this study will 
provide new insights in the role of peripheral blood cells 
in insulin action, insulin resistance and interactions with 
key target tissues such as skeletal muscle and endocrine 
pancreas. 
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